Pseudomonas Infections
11
3
3
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
18.2%
2 terminated out of 11 trials
66.7%
-19.8% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
Benefits and Risks of Newborn Screening for Cystic Fibrosis
Lcr35 / ICU / P. Aeruginosa
Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia